Articles tagged with: Denosumab
Headline, News »
The majority of multiple myeloma patients suffer from bone disease, and drugs called bisphosphonates are commonly used to help improve bone health in myeloma patients. Dr. David Roodman of the University of Pittsburgh discussed the current use of bisphosphonates in multiple myeloma during an education session on June 7 at the annual American Society of Clinical Oncology (ASCO) meeting.
Treatment of myeloma bone disease is important, since 20 percent of multiple myeloma patients experience a fracture at the time of their myeloma diagnosis, and 60 percent of multiple myeloma patients…
Headline, News »
Yesterday was the fourth day of the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. Although today is the final day of the meeting, the multiple myeloma-related sessions concluded yesterday.
The day began with a meeting-wide session to review the highlights of the previous day across all cancer types. There were six presentations, and despite all of the types of cancers being discussed at the meeting, an entire presentation was devoted to myeloma.
Dr. Jean-Luc Harousseau from the Rene Gauducheau Cancer Center in France presented the myeloma highlights.…
News »
FDA Requests Additional Information For Prolia Approval – Amgen Inc. announced on Monday that the U.S. Food and Drug Administration (FDA) has requested additional information needed for the agency to complete its review of Prolia (denosumab). Amgen has applied to the FDA to have Prolia approved for the treatment and prevention of postmenopausal osteoporosis. In its recent information request, the FDA asked Amgen for all updated Prolia safety data as well as more details about Amgen’s proposed post-marketing surveillance program for Prolia. The Agency also informed Amgen that a new clinical trial program will be necessary for the FDA to be able to approve Prolia for the prevention of postmenopausal osteoporosis. Prolia is currently being tested in multiple myeloma patients to see if it can delay skeletal events (see related Beacon article). For more information, please see the Amgen press release.
Race For Research 5K Walk/Run – On November 1, the Multiple Myeloma Research Foundation will be sponsoring the Race for Research 5K Walk/Run in Atlanta, Georgia. Registration starts at 7 a.m. and the race beings at 8:30 a.m. The MMRF is looking for participants and donations for this event. For more information, please visit the MMRF Web site.
RHS Open – On November 2, the International Myeloma Foundation is holding the Inaugural RHS open in Mt. Pleasant, SC. This annual golf tournament is held in honor of IMF Board Member, Rich Saletan. For more information, to register, or to sponsor a golfer, please visit the IMF Web site.
For a more detailed listing of myeloma related events, please check the Myeloma Beacon Events Calendar.
Headline, News »
On Monday, Amgen released results from its Phase 3 clinical trial that compared denosumab with Zometa (zoledronic acid) in advanced cancer patients whose tumors have spread to the bone. The results indicated that denosumab delayed skeletal related events in this group of cancer patients.
Tumors that migrate to bone tissue, called bone metastases, are a major concern for patients with advanced multiple myeloma. Bone metastases often weaken and destroy the bone surrounding the tumor, resulting in serious complications that include bone fractures, spinal cord compression, the need for…
News »
At the recent twelfth annual International Myeloma Workshop (IMW), physicians discussed strategies for managing multiple myeloma symptoms. Their topics included deep vein thrombosis (DVT), a potentially fatal blood clot in the body’s large veins, and myeloma-induced bone disease, including “soft spots” and fractures.
DVT involves blood clot formation in the deep veins of the body, and if a clot dislodges, it may travel to other areas and block blood flow to vital organs. Researchers estimate that approximately 70 percent of all critical blockages of lung blood vessels originate from DVT…